|
References
Supporting documents for claims found in this Website
a
b
Mayer EA (2008). "Clinical
practice. Irritable bowel syndrome". N. Engl. J. Med.
358 (16): 1692–9.
doi:10.1056/NEJMcp0801447.
PMID 18420501.
Intestinal
Infection
Yang CM, Li YQ
(2007). "[The therapeutic effects of eliminating allergic foods
according to food-specific IgG antibodies in irritable bowel
syndrome]" (in Chinese). Zhonghua Nei Ke Za Zhi 46
(8): 641–3.
PMID 17967233.
a
b
c
Stark D, van Hal S, Marriott D, Ellis J, Harkness J (2007).
"Irritable bowel syndrome: a review on the role of intestinal
protozoa and the importance of their detection and diagnosis".
Int. J. Parasitol. 37 (1): 11–20.
doi:10.1016/j.ijpara.2006.09.009.
PMID 17070814.
Schmulson MW,
Chang L (1999). "Diagnostic approach to the patient with
irritable bowel syndrome". Am. J. Med. 107 (5A):
20S–26S.
doi:10.1016/S0002-9343(99)00278-8.
PMID 10588169.
a
b
Talley NJ (2006). "Irritable
bowel syndrome". Intern Med J 36 (11): 724–8.
doi:10.1111/j.1445-5994.2006.01217.x.
PMID 17040359.
Holten KB,
Wetherington A, Bankston L (2003). "Diagnosing
the patient with abdominal pain and altered bowel habits: is it
irritable bowel syndrome?". Am Fam Physician 67
(10): 2157–62.
PMID 12776965.
a
b
Yawn BP, Lydick E, Locke GR, Wollan PC, Bertram SL, Kurland MJ
(2001). "Do published guidelines for evaluation of irritable
bowel syndrome reflect practice?". BMC gastroenterology
1: 11.
doi:10.1186/1471-230X-1-11.
PMID 11701092.
a
b
Fass R, Longstreth GF, Pimentel M, et al (2001).
"Evidence- and consensus-based practice guidelines for the
diagnosis of irritable bowel syndrome". Arch. Intern. Med.
161 (17): 2081–8.
doi:10.1001/archinte.161.17.2081.
PMID 11570936.
Talley NJ
(2006). "A unifying hypothesis for the functional
gastrointestinal disorders: really multiple diseases or one
irritable gut?". Reviews in gastroenterological disorders
6 (2): 72–8.
PMID 16699476.
Spiegel BM,
DeRosa VP, Gralnek IM, Wang V, Dulai GS (2004). "Testing for
celiac sprue in irritable bowel syndrome with predominant
diarrhea: a cost-effectiveness analysis". Gastroenterology
126 (7): 1721–32.
doi:10.1053/j.gastro.2004.03.012.
PMID 15188167.
Drisko et al
(2006). "Treating Irritable Bowel Syndrome with a Food
Elimination Diet Followed by Food Challenge and Probiotics".
Journal of the American College of Nutrition 25 (6):
514–22.
PMID 17229899.
Vernia P,
Ricciardi MR, Frandina C, Bilotta T, Frieri G (1995). "Lactose
malabsorption and irritable bowel syndrome. Effect of a
long-term lactose-free diet". The Italian journal of
gastroenterology 27 (3): 117–21.
PMID 7548919.
http://digestive.niddk.nih.gov/ddiseases/pubs/celiac/
- The United States National Institutes of Health Celiac Disease
Page
Cole JA, Rothman
KJ, Cabral HJ, Zhang Y, Farraye FA (2006). "Migraine,
fibromyalgia, and depression among people with IBS: a
prevalence study". BMC gastroenterology 6: 26.
doi:10.1186/1471-230X-6-26.
PMID 17007634.
Kurland JE,
Coyle WJ, Winkler A, Zable E (2006). "Prevalence of irritable
bowel syndrome and depression in
fibromyalgia". Dig. Dis. Sci. 51 (3): 454–60.
doi:10.1007/s10620-006-3154-7.
PMID 16614951.
Frissora CL,
Koch KL (2005). "Symptom overlap and comorbidity of irritable
bowel syndrome with other conditions". Current
gastroenterology reports 7 (4): 264–71.
doi:10.1007/s11894-005-0018-9.
PMID 16042909.
a
b
Bercik P, Verdu EF, Collins SM (2005). "Is irritable bowel
syndrome a low-grade inflammatory bowel disease?".
Gastroenterol. Clin. North Am. 34 (2): 235–45,
vi-vii.
doi:10.1016/j.gtc.2005.02.007.
PMID 15862932.
a
b
Quigley EM (2005). "Irritable bowel syndrome and inflammatory
bowel disease: interrelated diseases?". Chinese journal of
digestive diseases 6 (3): 122–32.
doi:10.1111/j.1443-9573.2005.00202.x.
PMID 16045602.
a
b
Simrén M, Axelsson J, Gillberg R, Abrahamsson H, Svedlund J,
Björnsson ES (2002). "Quality of life in inflammatory bowel
disease in remission: the impact of IBS-like symptoms and
associated psychological factors". Am. J. Gastroenterol.
97 (2): 389–96.
PMID 11866278.
a
b
Minderhoud IM, Oldenburg B, Wismeijer JA, van Berge Henegouwen
GP, Smout AJ (2004). "IBS-like symptoms in patients with
inflammatory bowel disease in remission; relationships with
quality of life and coping behavior". Dig. Dis. Sci.
49 (3): 469–74.
doi:10.1023/B:DDAS.0000020506.84248.f9.
PMID 15139501.
a
b
García Rodríguez LA, Ruigómez A, Wallander MA, Johansson S, Olbe
L (2000). "Detection of colorectal tumor and inflammatory bowel
disease during follow-up of patients with initial diagnosis of
irritable bowel syndrome". Scand. J. Gastroenterol. 35
(3): 306–11.
doi:10.1080/003655200750024191.
PMID 10766326.
Corazziari et
al. (2008). "Gallstones, cholecystectomy and irritable bowel
syndrome (IBS) MICOL population-based study.". Dig Liver Dis..
doi:10.1016/j.dld.2008.02.013.
PMID 18406218.
Cole JA, Yeaw JM,
Cutone JA, et al (2005). "The incidence of abdominal and
pelvic surgery among patients with irritable bowel syndrome".
Dig. Dis. Sci. 50 (12): 2268–75.
doi:10.1007/s10620-005-3047-1.
PMID 16416174.
Longstreth GF,
Yao JF (2004). "Irritable bowel syndrome and surgery: a
multivariable analysis". Gastroenterology 126 (7):
1665–73.
doi:10.1053/j.gastro.2004.02.020.
PMID 15188159.
Tietjen GE,
Bushnell CD, Herial NA, Utley C, White L, Hafeez F (2007).
"Endometriosis is associated with prevalence of comorbid
conditions in migraine". Headache 47 (7): 1069–78.
doi:10.1111/j.1526-4610.2007.00784.x.
PMID 17635599.
Interstitial
cystitis (Mayo Clinic)
Thabane M,
Kottachchi DT, Marshall JK (2007). "The incidence and prognosis
of post-infectious irritable bowel syndrome.". Aliment
Pharmacol Ther 26 (4): 535–44.
PMID 17661757.
El-Omar EM,
Carrington M, Chow WH, et al (2000). "Interleukin-1
polymorphisms associated with increased risk of gastric cancer".
Nature 404 (6776): 398–402.
doi:10.1038/35006081.
PMID 10746728.
Brown PW (1950).
"The irritable bowel syndrome". Rocky Mountain medical
journal 47 (5): 343–6.
PMID 15418074.
Whitehead WE,
Winget C, Fedoravicius AS, Wooley S, Blackwell B (1982).
"Learned illness behavior in patients with irritable bowel
syndrome and peptic ulcer". Dig. Dis. Sci. 27 (3):
202–8.
doi:10.1007/BF01296915.
PMID 7075418.
Svedlund J,
Sjödin I (1985). "A psychosomatic approach to treatment in the
irritable bowel syndrome and peptic ulcer disease with aspects
of the design of clinical trials". Scand. J. Gastroenterol.
Suppl. 109: 147–51.
doi:10.3109/00365528509103950.
PMID 3895386.
Damianos AJ,
McGarrity TJ (1997). "Treatment strategies for Helicobacter
pylori infection". American family physician 55
(8): 2765–74, 2784–6.
PMID 9191460.
Fukudo S, Nomura
T, Muranaka M, Taguchi F (1993). "Brain-gut response to stress
and cholinergic stimulation in irritable bowel syndrome. A
preliminary study". J. Clin. Gastroenterol. 17
(2): 133–41.
doi:10.1097/00004836-199309000-00009.
PMID 8031340.
Orr WC, Crowell
MD, Lin B, Harnish MJ, Chen JD (1997). "Sleep and gastric
function in irritable bowel syndrome: derailing the brain-gut
axis". Gut 41 (3): 390–3.
PMID 9378397.
Miwa J, Echizen
H, Matsueda K, Umeda N (2001). "Patients with
constipation-predominant irritable bowel syndrome (IBS) may have
elevated serotonin concentrations in colonic mucosa as compared
with diarrhea-predominant patients and subjects with normal
bowel habits". Digestion 63 (3): 188–94.
doi:10.1159/000051888.
PMID 11351146.
McGowan K, Kane
A, Asarkof N, et al (1983). "Entamoeba histolytica causes
intestinal secretion: role of serotonin". Science 221
(4612): 762–4.
doi:10.1126/science.6308760.
PMID 6308760.
McGowan K,
Guerina V, Wicks J, Donowitz M (1985). "Secretory hormones of
Entamoeba histolytica". Ciba Found. Symp. 112:
139–54.
PMID 2861068.
Banu, Naheed, et
al. (2005). "Neurohumoral
alterations and their role in amoebiasis." (PDF). Indian
J. Clin Biochem 20 (2): 142–5.
doi:10.1007/BF02867414.
Gwee KA, Collins
SM, Read NW, et al (2003). "Increased rectal mucosal
expression of interleukin 1beta in recently acquired
post-infectious irritable bowel syndrome". Gut 52
(4): 523–6.
doi:10.1136/gut.52.4.523.
PMID 12631663.
Liebregts T,
Adam B, Bredack C, et al (2007). "Immune activation in
patients with irritable bowel syndrome". Gastroenterology
132 (3): 913–20.
doi:10.1053/j.gastro.2007.01.046.
PMID 17383420.
Cenac N, Andrews
CN, Holzhausen M, et al (2007). "Role for protease
activity in visceral pain in irritable bowel syndrome". J.
Clin. Invest. 117 (3): 636–47.
doi:10.1172/JCI29255.
PMID 17304351.
Hussain R,
Jaferi W, Zuberi S, et al (1997). "Significantly
increased IgG2 subclass antibody levels to Blastocystis hominis
in patients with irritable bowel syndrome". Am. J. Trop. Med.
Hyg. 56 (3): 301–6.
PMID 9129532.
a
b
Stephen Wangen
(2006). Irritable bowel syndrome solution. Seattle, WA:
Innate Health Group.
ISBN 0-9768537-8-7.
Excerpted with author's permission at
[1]
Spiegel BM,
et al (2004). "Testing for celiac sprue in irritable bowel
syndrome with predominant diarrhea: a cost-effectiveness
analysis.". Gastroenterology 126 (7): 1721–32.
doi:10.1053/j.gastro.2004.03.012.
PMID 15188167.
Shahbazkhani B,
et al (2003). "Coeliac disease presenting with symptoms
of irritable bowel syndrome.". Aliment Pharmacol Therapy
18 (2): 231–5.
doi:10.1046/j.1365-2036.2003.01666.x.
PMID 12869084.
Li H, et al
(2007). "Allergen-IgE complexes trigger CD23-dependent CCL20
release from human intestinal epithelial cells.".
Gastroenterology 133 (6): 1905–15.
doi:10.1053/j.gastro.2007.09.024.
PMID 18054562.
"The therapeutic
effects of eliminating allergic foods according to food-specific
IgG antibodies in irritable bowel syndrome - Article in Chinese"
(2007). Zhonghua Nei Ke Za Zhi. 46 (8): 641–3.
PMID 17967233.
Drisko et al
(2006). "Treating Irritable Bowel Syndrome with a Food
Elimination Diet Followed by Food Challenge and Probiotics".
Journal of the American College of Nutrition 25 (6):
514–22.
PMID 17229899.
Johnson, David.
(2006). "Viewpoints:
Efficacy of Rifaximin vs Placebo in Reducing Symptoms in Adults
With IBS.". Medscape Gastroenterology 8 (2).
a
b
Pimentel M, Park S, Mirocha J, Kane SV, Kong Y (2006). "The
effect of a nonabsorbed oral antibiotic (rifaximin) on the
symptoms of the irritable bowel syndrome: a randomized trial".
Ann. Intern. Med. 145 (8): 557–63.
PMID 17043337.
Posserud I,
Stotzer PO, Björnsson ES, Abrahamsson H, Simrén M (2007). "Small
intestinal bacterial overgrowth in patients with irritable bowel
syndrome". Gut 56 (6): 802–8.
doi:10.1136/gut.2006.108712.
PMID 17148502.
a
b
Yakoob J, Jafri W, Jafri N, et al (2004). "Irritable
bowel syndrome: in search of an etiology: role of Blastocystis
hominis". Am. J. Trop. Med. Hyg. 70 (4): 383–5.
PMID 15100450.
a
b
Giacometti A, Cirioni O, Fiorentini A, Fortuna M, Scalise G
(1999). "Irritable bowel syndrome in patients with Blastocystis
hominis infection". Eur. J. Clin. Microbiol. Infect. Dis.
18 (6): 436–9.
doi:10.1007/s100960050314.
PMID 10442423.
Qadri SM, al-Okaili
GA, al-Dayel F (1989). "Clinical significance of Blastocystis
hominis". J. Clin. Microbiol. 27 (11): 2407–9.
PMID 2808664.
Markell EK,
Udkow MP (1986). "Blastocystis hominis: pathogen or fellow
traveler?". Am. J. Trop. Med. Hyg. 35 (5): 1023–6.
PMID 3766850.
Windsor J
(2007). "B.
hominis and D. fragilis: Neglected human protozoa".
British Biomedical Scientist: 524–7.
Stensvold R,
Brillowska-Dabrowska A, Nielsen HV, Arendrup MC (2006).
"Detection of Blastocystis hominis in unpreserved stool
specimens by using polymerase chain reaction". J. Parasitol.
92 (5): 1081–7.
doi:10.1645/GE-840R.1.
PMID 17152954.
Yakoob J, Jafri
W, Jafri N, Islam M, Asim Beg M (2004). "In vitro susceptibility
of Blastocystis hominis isolated from patients with irritable
bowel syndrome". Br. J. Biomed. Sci. 61 (2): 75–7.
PMID 15250669.
Haresh K, Suresh
K, Khairul Anus A, Saminathan S (1999). "Isolate resistance of
Blastocystis hominis to metronidazole". Trop. Med. Int.
Health 4 (4): 274–7.
doi:10.1046/j.1365-3156.1999.00398.x.
PMID 10357863.
Markell EK,
Udkow MP (1986). "Blastocystis hominis: pathogen or fellow
traveler?". Am. J. Trop. Med. Hyg. 35 (5): 1023–6.
PMID 3766850.
Ok UZ,
Girginkardeşler N, Balcioğlu C, Ertan P, Pirildar T, Kilimcioğlu
AA (1999). "Effect of trimethoprim-sulfamethaxazole in
Blastocystis hominis infection". Am. J. Gastroenterol.
94 (11): 3245–7.
doi:10.1111/j.1572-0241.1999.01529.x.
PMID 10566723.
a
b
Lagacé-Wiens PR, VanCaeseele PG, Koschik C (2006). "Dientamoeba
fragilis: an emerging role in intestinal disease". CMAJ :
Canadian Medical Association journal = journal de l'Association
medicale canadienne 175 (5): 468–9.
doi:10.1503/cmaj.060265.
PMID 16940260.
Amin OM (2002).
"Seasonal prevalence of intestinal parasites in the United
States during 2000". Am. J. Trop. Med. Hyg. 66
(6): 799–803.
PMID 12224595.
a
b
Stensvold CR, Arendrup MC, Mølbak K, Nielsen HV (2007). "The
prevalence of Dientamoeba fragilis in patients with suspected
enteroparasitic disease in a metropolitan area in Denmark".
Clin. Microbiol. Infect. 13 (8): 839–42.
doi:10.1111/j.1469-0691.2007.01760.x.
PMID 17610603.
Borody T, Warren
E, Wettstein A, et al. (2002). "Eradication of Dientamoeba
fragilis can resolve IBS-like symptoms.". J Gastroenterol
Hepatol 17 (Suppl; pages=A103).
Halpert AD,
Thomas AC, Hu Y, Morris CB, Bangdiwala SI, Drossman DA (2006).
"A survey on patient
educational needs in irritable
bowel syndrome and attitudes toward participation in clinical
research". J Clin Gastroenterol 40 (1): 37–43.
doi:10.1097/01.mcg.0000190759.95862.08.
PMID 16340632.
Heather
Van Vorous (2000). Eating for IBS: 175 Delicious, Nutritious,
Low-Fat, Low-Residue Recipes to Stabilize the Touchiest Tummy.
Marlowe & Company.
ISBN 1-56924-600-9.
Excerpted with author's permission at
Help for Irritable Bowel Syndrome (see IBS Diet Section)
Atkinson W,
Sheldon TA, Shaath N, Whorwell PJ (2004). "Food
elimination based on IgG antibodies in irritable bowel syndrome:
a randomised controlled trial". Gut 53 (10):
1459–64.
doi:10.1136/gut.2003.037697.
PMID 15361495.
Sjölund K, Ekman
R, Lindgren S, Rehfeld J (1996). "Disturbed motilin and
cholecystokinin release in the irritable bowel syndrome.".
Scand J Gastroenterol 31 (11): 1110–4.
doi:10.3109/00365529609036895.
PMID 8938905.
Caldarella MP,
Milano A, Laterza F, Sacco F, Balatsinou C, Lapenna D,
Pierdomenico SD, Cuccurullo F, Neri M (2005). "Visceral
sensitivity and symptoms in patients with constipation- or
diarrhea-predominant irritable bowel syndrome (IBS): effect of a
low-fat intraduodenal infusion". Am J Gastroenterol
100 (2): 383–9.
doi:10.1111/j.1572-0241.2005.40100.x.
PMID 15667496.
Choi, Y. Fats, Fructose May Contribute to IBS
Symptoms. ACG 68th Annual Scientific Meeting: Abstract 21,
presented
October 13,
2003;
Abstract 547, presented
October 14, 2003.
Zar S, Benson MJ,
Kumar D (2005). "Food-specific serum IgG4 and IgE titers to
common food antigens in irritable bowel syndrome". Am J
Gastroenterol 100 (7): 1550–7.
doi:10.1111/j.1572-0241.2005.41348.x.
PMID 15984980.
Zar S, Mincher
L, Benson MJ, Kumar D (2005). "Food-specific IgG4
antibody-guided exclusion diet improves symptoms and rectal
compliance in irritable bowel syndrome". Scand J
Gastroenterol 40 (7): 800–7.
doi:10.1080/00365520510015593.
PMID 16109655.
Mayer EA, Berman
S, Suyenobu B, Labus J, Mandelkern MA, Naliboff BD, Chang L
(2005). "Differences in brain responses to visceral pain between
patients with irritable bowel syndrome and ulcerative colitis".
Pain 115 (3): 398–409.
PMID 15911167.
a
b
Bijkerk C, Muris J, Knottnerus J, Hoes A, de Wit N (2004).
"Systematic review: the role of different types of fiber in the
treatment of irritable bowel syndrome.". Aliment Pharmacol
Ther 19 (3): 245–51.
doi:10.1111/j.0269-2813.2004.01862.x.
PMID 14984370.
Prior A,
Whorwell P (1987). "Double blind study of ispaghula in irritable
bowel syndrome.". Gut 28 (11): 1510–3.
doi:10.1136/gut.28.11.1510.
PMID 3322956.
Jalihal A,
Kurian G (1990). "Ispaghula therapy in irritable bowel syndrome:
improvement in overall well-being is related to reduction in
bowel dissatisfaction.". J Gastroenterol Hepatol 5
(5): 507–13.
doi:10.1111/j.1440-1746.1990.tb01432.x.
PMID 2129822.
Kumar A, Kumar
N, Vij J, Sarin S, Anand B (1987). "Optimum dosage of ispaghula
husk in patients with irritable bowel syndrome: correlation of
symptom relief with whole gut transit time and stool weight.".
Gut 28 (2): 150–5.
doi:10.1136/gut.28.2.150.
PMID 3030900.
Francis CY,
Whorwell PJ (1994). "Bran and irritable bowel syndrome: time for
reappraisal". Lancet 344 (8914): 39–40.
doi:10.1016/S0140-6736(94)91055-3.
PMID 7912305.
Cann P, Read N,
Holdsworth C, Barends D (1984). "Role of loperamide and placebo
in management of irritable bowel syndrome (IBS).". Dig Dis
Sci 29 (3): 239–47.
doi:10.1007/BF01296258.
PMID 6365490.
Cann P, Read N,
Holdsworth C (1984). "What is the benefit of coarse wheat bran
in patients with irritable bowel syndrome?". Gut 25
(2): 168–73.
doi:10.1136/gut.25.2.168.
PMID 6319244.
a
b
Quartero A, Meineche-Schmidt V, Muris J, Rubin G, de Wit N
(2005). "Bulking agents, antispasmodic and antidepressant
medication for the treatment of irritable bowel syndrome.".
Cochrane Database Syst Rev: CD003460.
doi:10.1002/14651858.CD003460.pub2.
PMID 15846668.
Lesbros-Pantoflickova
D, Michetti P, Fried M, Beglinger C, Blum A (2004).
"Meta-analysis: The treatment of irritable bowel syndrome.".
Aliment Pharmacol Ther 20 (11-12): 1253–69.
doi:10.1111/j.1365-2036.2004.02267.x.
PMID 15606387.
Jailwala J,
Imperiale T, Kroenke K (2000). "Pharmacologic treatment of the
irritable bowel syndrome: a systematic review of randomized,
controlled trials.". Ann Intern Med 133 (2):
136–47.
PMID 10896640.
Joo J,
Ehrenpreis E, Gonzalez L, Kaye M, Breno S, Wexner S, Zaitman D,
Secrest K (1998). "Alterations in colonic anatomy induced by
chronic stimulant laxatives: the cathartic colon revisited.".
J Clin Gastroenterol 26 (4): 283–6.
doi:10.1097/00004836-199806000-00014.
PMID 9649012.
Talley N (2001).
"Serotoninergic neuroenteric modulators.". Lancet 358
(9298): 2061–8.
doi:10.1016/S0140-6736(01)07103-3.
PMID 11755632.
Evans B, Clark
W, Moore D, Whorwell P (2004). "Tegaserod for the treatment of
irritable bowel syndrome.". Cochrane Database Syst Rev:
CD003960.
doi:10.1002/14651858.CD003960.pub2.
PMID 14974049.
Tack J,
Broekaert D, Fischler B, Oudenhove L, Gevers A, Janssens J
(2006). "A controlled crossover study of the selective serotonin
reuptake inhibitor citalopram in irritable bowel syndrome.".
Gut 55 (8): 1095–103.
doi:10.1136/gut.2005.077503.
PMID 16401691.
Vahedi H, Merat
S, Rashidioon A, Ghoddoosi A, Malekzadeh R (2005). "The effect
of fluoxetine in patients with pain and constipation-predominant
irritable bowel syndrome: a double-blind randomized-controlled
study.". Aliment Pharmacol Ther 22 (5): 381–5.
doi:10.1111/j.1365-2036.2005.02566.x.
PMID 16128675.
Creed F,
Fernandes L, Guthrie E, Palmer S, Ratcliffe J, Read N, Rigby C,
Thompson D, Tomenson B (2003). "The cost-effectiveness of
psychotherapy and paroxetine for severe irritable bowel
syndrome.". Gastroenterology 124 (2): 303–17.
doi:10.1053/gast.2003.50055.
PMID 12557136.
Tabas G, Beaves
M, Wang J, Friday P, Mardini H, Arnold G (2004). "Paroxetine to
treat irritable bowel syndrome not responding to high-fiber
diet: a double-blind, placebo-controlled trial.". Am J
Gastroenterol 99 (5): 914–20.
doi:10.1111/j.1572-0241.2004.04127.x.
PMID 15128360.
Jackson J,
O'Malley P, Tomkins G, Balden E, Santoro J, Kroenke K (2000).
"Treatment of functional gastrointestinal disorders with
antidepressant medications: a meta-analysis.". Am J Med
108 (1): 65–72.
doi:10.1016/S0002-9343(99)00299-5.
Drossman D,
Toner B, Whitehead W, Diamant N, Dalton C, Duncan S, Emmott S,
Proffitt V, Akman D, Frusciante K, Le T, Meyer K, Bradshaw B,
Mikula K, Morris C, Blackman C, Hu Y, Jia H, Li J, Koch G,
Bangdiwala S (2003). "Cognitive-behavioral therapy versus
education and desipramine versus placebo for moderate to severe
functional bowel disorders.". Gastroenterology 125
(1): 19–31.
doi:10.1016/S0016-5085(03)00669-3.
Sharara AI, Aoun
E, Abdul-Baki H, Mounzer R, Sidani S, Elhajj I (2006). "A
randomized double-blind placebo-controlled trial of rifaximin in
patients with abdominal bloating and flatulence". Am J
Gastroenterol 101 (2): 326–33.
doi:10.1111/j.1572-0241.2006.00458.x.
Quigley EM
(2006). "Germs, gas and the gut; the evolving role of the
enteric flora in IBS". Am J Gastroenterol 101 (2):
334–5.
doi:10.1111/j.1572-0241.2006.00445.x.
Madisch A,
Holtmann G, Plein K, Holz J (2004). "Treatment of irritable
bowel syndrome with herbal preparations: results of a
double-blind, randomized, placebo-controlled, multi-centre
trial". Aliment Pharmacol Ther 19: 271–9.
doi:10.1111/j.1365-2036.2004.01859.x.
Hadley SK,
Gaarder SM (2005). "Treatment
of irritable bowel syndrome". Am Fam Physician 72
(12): 2501–6.
PMID 16370407.
Nash P, Gould
SR, Bernardo DE (1986). "Peppermint oil does not relieve the
pain of irritable bowel syndrome". Br J Clin Pract 40
(7): 292–3.
PMID 3527248.
Liu JH, Chen GH,
Yeh HZ, Huang CK, Poon SK (1997). "Enteric-coated peppermint-oil
capsules in the treatment of irritable bowel syndrome: a
prospective, randomized trial". J. Gastroenterol. 32
(6): 765–8.
PMID 9430014.
Warfield,
Carol A.; Zahid H. Bajwa (2003). Principles and Practice of
Pain Medicine. McGraw-Hill Professional.
ISBN 0071443495.
Massa F, Storr
M, Lutz B (2005). "The endocannabinoid system in the physiology
and pathophysiology of the gastrointestinal tract.". J Mol
Med 83 (12): 944–54.
doi:10.1007/s00109-005-0698-5.
Russo EB (2004).
"Clinical endocannabinoid deficiency (CECD): can this concept
explain therapeutic benefits of cannabis in migraine,
fibromyalgia, irritable bowel syndrome and other
treatment-resistant conditions?". Neuro Endocrinol. Lett.
25 (1-2): 31–9.
PMID 15159679.
Kennedy T, Jones
R, Darnley S, Seed P, Wessely S, Chalder T (2005). "Cognitive
behaviour therapy in addition to antispasmodic treatment for
irritable bowel syndrome in primary care: randomised controlled
trial". BMJ 331 (7514): 435.
doi:10.1136/bmj.38545.505764.06.
PMID 16093252
Full text.
Heymann-Mönnikes
I, Arnold R, Florin I, Herda C, Melfsen S, Mönnikes H (2000).
"The combination of medical treatment plus multicomponent
behavioral therapy is superior to medical treatment alone in the
therapy of irritable bowel syndrome.". Am J Gastroenterol
95 (4): 981–94.
PMID 10763948.
Gonsalkorale WM,
Miller V, Afzal A, Whorwell PJ (2003). "Long term benefits of
hypnotherapy for irritable bowel syndrome". Gut 52
(11): 1623–9.
doi:10.1136/gut.52.11.1623.
PMID 14570733.
van der Veek PP,
van Rood YR, Masclee AA (2007). "Clinical trial: short- and
long-term benefit of relaxation training for irritable bowel
syndrome". Aliment. Pharmacol. Ther. 26 (6):
943–52.
doi:10.1111/j.1365-2036.2007.03437.x.
PMID 17767479.
Niedzielin K,
Kordecki H, Birkenfeld B (2001). "A controlled, double-blind,
randomized study on the efficacy of
Lactobacillus plantarum 299V in patients with irritable
bowel syndrome". Eur J Gastroenterol Hepatol 13
(10): 1143–7.
doi:10.1097/00042737-200110000-00004.
PMID 11711768.
New
Studies Examine the Evidence of Probiotics on IBS (Oct
2005). American College of Gastrointerologists. Retrieved on
March 2,
2006
Maupas J,
Champemont P, Delforge M (1983). "Treatment of irritable bowel
syndrome with Saccharomyces boulardii: a double blind,
placebo controlled study". Medicine Chirurgie Digestives
12(1): 77–9.
Lim B, Manheimer
E, Lao L, Ziea E, Wisniewski J, Liu J, Berman B (2006).
"Acupuncture for treatment of irritable bowel syndrome.".
Cochrane Database Syst Rev: CD005111.
doi:10.1002/14651858.CD005111.pub2.
PMID 17054239.
Irritable
Bowel Syndrome - A Traditional Chinese Medicine Perspective,
(2006). Al Stone L.Ac. Retrieved on
February 14,
2006.
Get
the Facts, Acupuncture, (2006). National Institute of
Health. Retrieved on
March 2,
2006.
a
b
c
Boivin M. (2001 Oct;15). "Socioeconomic impact of irritable
bowel syndrome in". Canada. Can J Gastroenterol. Suppl
B: :8B–11B..
PMID 11694908.
a
b
c
Quigley EM, Locke GR, Mueller-Lissner S, Paulo LG, Tytgat GN,
Helfrich I, Schaefer E. Prevalence and management of abdominal
cramping and pain: a multinational survey. (2006 Jul). "Aliment
Pharmacol Ther.". Alimentary Pharmacology & Therapeutics
24 (2): 411–9.
doi:10.1111/j.1365-2036.2006.02989.x.
PMID 16842469.
Ehlin AG,
Montgomery SM, Ekbom A, Pounder RE, Wakefield AJ. (2003 Aug).
"Prevalence of gastrointestinal diseases in two British national
birth cohorts.". Gut. 52 (8): 1117–21..
doi:10.1136/gut.52.8.1117.
PMID 12865268.
a
b
Wilson S, Roberts L, Roalfe A, Bridge P, Singh S. (2004).
"Prevalence of irritable bowel syndrome: a community survey.".
Br J Gen Pract. 54 (504): 495–502..
PMID 15239910.
Hungin AP, Chang
L, Locke GR, Dennis EH, Barghout V (2005). "Irritable bowel
syndrome in the United States: prevalence, symptom patterns and
impact". Aliment. Pharmacol. Ther. 21 (11):
1365–75.
doi:10.1111/j.1365-2036.2005.02463.x.
PMID 15932367.
Jafri W, Yakoob
J, Jafri N Islam M, Ali QM. (2007). "Irritable bowel syndrome
and health seeking behaviour in different communities of
Pakistan.". J Pak Med Assoc. 57 (6): 285–7.
PMID 17629228.
Jafri W, Yakoob
J, Jafri N, Islam M, Ali QM. (2005). "Frequency of irritable
bowel syndrome in college students.". J Ayub Med Coll
Abbottabad. 4 (17): 9–11.
PMID 16599025.
a
b
Schmulson M, Ortiz O, Santiago-Lomeli M, Gutierrez-Reyes G,
Gutierrez-Ruiz MC, Robles-Diaz G, Morgan D. (2006). "Frequency
of functional bowel disorders among healthy volunteers in Mexico
City." (PDF). Dig Dis. 24: 342.
doi:10.1159/000092887.
PMID 16849861.
Tuteja AK,
Talley NJ, Gelman SS, Adler SC, Thompson C, Tolman K, Hale DC.
E. (2007). "Development of Functional Diarrhea, Constipation,
Irritable Bowel Syndrome, and Dyspepsia During and After
Traveling Outside the USA.". Dig. Dis. Sci 53:
271.
doi:10.1007/s10620-007-9853-x.
PMID 17549631.
a
b
Hulisz D. (2004). "The burden of illness of irritable bowel
syndrome: current challenges and hope for the future.". J
Manag Care Pharm. 10 (4): 299–309.
PMID 15298528.
a
b
Levy RL, Von Korff M, Whitehead WE, Stang P, Saunders K,
Jhingran P, Barghout V, Feld AD. (2001). "Costs of care for
irritable bowel syndrome patients in a health maintenance
organization". Am J Gastroenterol 96 (11): 3122–9.
doi:10.1111/j.1572-0241.2001.05258.x.
PMID 11721759.
a
b
Nyrop KA, Palsson OS, Levy RL, Korff MV, Feld AD, Turner MJ,
Whitehead WE. (2007). "Costs of health care for irritable bowel
syndrome, chronic constipation, functional diarrhoea and
functional abdominal pain.". Aliment Pharmacol Ther 26
(2): 237–48.
PMID 17593069.
a
b
Paré P, Gray J, Lam S, et al (2006). "Health-related
quality of life, work productivity, and health care resource
utilization of subjects with irritable bowel syndrome: baseline
results from LOGIC (Longitudinal Outcomes Study of
Gastrointestinal Symptoms in Canada), a naturalistic study".
Clinical therapeutics 28 (10): 1726–35; discussion
1710–1.
doi:10.1016/j.clinthera.2006.10.010.
PMID 17157129.
Leong SA,
Barghout V, Birnbaum HG, et al (2003). "The economic
consequences of irritable bowel syndrome: a US employer
perspective". Arch. Intern. Med. 163 (8): 929–35.
doi:10.1001/archinte.163.8.929.
PMID 12719202.
Martin B,
Ganguly R, Pannicker S, Feride F, Barghout V (2003). "Utilization
Patterns and Net Direct Medical Costs Medicaid of Irritable
Bowel Syndrome". Curr Med Res Opin 19 (8):
771–80.
doi:10.1185/030079903125002540.
PMID 12719202.
Maxion-Bergemann
S, Thielecke F, Abel F, Bergemann R (2006). "Costs of irritable
bowel syndrome in the UK and US". PharmacoEconomics 24
(1): 21–37.
doi:10.2165/00019053-200624010-00002.
PMID 16445300.
|
